Therapeutic strategies targeting this immunological cascade, particularly monoclonal antibodies directed against IL-17 and IL-23, have dramatically improved the management of moderate-to-severe plaque psoriasis. This evidence concerns the gene IL17A and psoriasis vulgaris.